Tuesday, May 14, 2013 10:09:26 AM
VSTA love the planking on the chart. One big flat line with no volume in sight.
Trade quality grade: F
Trade quality grade: F
Recent VTGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:52:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:51:49 PM
- Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer • Business Wire • 05/19/2026 12:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:26:37 PM
- Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:44:41 AM
- Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder • Business Wire • 05/12/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:30:08 PM
- Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder • Business Wire • 05/08/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:13:15 PM
- Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop • PR Newswire (US) • 04/28/2026 01:00:00 PM
- Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause • Business Wire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 09:27:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:43:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:41:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:40:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 12:33:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:16:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 08:45:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:10:38 PM
- Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN • PR Newswire (US) • 03/16/2026 06:38:00 AM
- Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN • PR Newswire (US) • 03/12/2026 07:29:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2026 11:02:20 AM
- Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN) • PR Newswire (US) • 03/10/2026 01:00:00 PM
